GLP-2 analog
Teduglutide (GLP-2)
Teduglutide has a mean terminal half-life of approximately 2 hours in healthy subjects and 1.3 hours in people with short bowel syndrome on the Gattex label; the app lists 2 hours.1
Teduglutide (GLP-2) after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- Teduglutide (GLP-2)
- Symbol
- TED
- Family
- GLP-1 and incretin
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Teduglutide is a glucagon-like peptide-2 (GLP-2) analog that binds glucagon-like peptide-2 receptors.1 Takeda markets it in the United States as Gattex, and the European Medicines Agency's product information names it Revestive.1,2 The app grades the evidence for teduglutide as strong; that grade rests on the short bowel syndrome trials described below, and the one trial outside short bowel syndrome among the sources cited here is a pilot study in Crohn's disease, which is not a label use.8
How it works
Sources in this part
The label describes teduglutide as an analog of naturally occurring human GLP-2, a peptide secreted by L-cells of the distal intestine.1 Receptor activation results in the local release of mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF).1 The European product information says the molecule is 33 amino acids long with a single substitution of alanine by glycine at position 2, which "results in resistance to in vivo degradation by the enzyme dipeptidyl peptidase-IV (DPP-IV), resulting in an extended half-life".2 In a 21-day open-label, dose-ranging study in 17 adults with SBS (2 to 3 per dose group) at daily doses of 0.03, 0.1 and 0.15 mg/kg, the label reports that all doses except 0.03 mg/kg "resulted in enhanced gastrointestinal fluid (wet weight) absorption of approximately 750 to 1000 mL/day".1 The European product information says that, based on pre-clinical findings and the proposed mechanism of action with trophic effects on intestinal mucosa, "there appears to be a risk for the promotion of small intestinal and/or colonic neoplasia", that the clinical studies "could neither exclude nor confirm such an increased risk", and that several cases of benign colorectal polyps occurred in the trials but the frequency was not increased compared to placebo-treated patients.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 88%
- Typical dose
- 1–5 mg/day
- Route
- SubQ
- Time to peak
- ~3.5 h
The second column of the table holds the app's own figures, shown beside what the labels and a healthy-subject study report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | 2 hours | Mean terminal half-life of approximately 2 hours in healthy subjects and 1.3 hours in SBS subjects on the US label; terminal elimination half-life of approximately 2 hours in the European product information1,2 |
| Bioavailability | 88% | Absolute bioavailability of 88% by subcutaneous injection in healthy subjects on the US label, and 88% in the European product information1,2 |
| Time to peak | 3.5 hours | Maximum plasma concentrations at 3 to 5 hours after administration on the US label; approximately 3-5 hours at all dose levels in the European product information1,2 |
| Dose basis | 1–5 mg/day | Both labels give the dose per kilogram of body weight, 0.05 mg/kg once daily, rather than a fixed mg/day figure1,2 |
The app's one-compartment model is consistent with a short half-life, and the label adds that "No accumulation of teduglutide was observed following repeated subcutaneous administrations".1 In healthy subjects the label gives a plasma clearance of about 123 mL/hr/kg, "similar to the GFR", which it reads as clearance primarily by the kidney.1 In adults with moderate to severe renal impairment or end-stage renal disease, exposure rose with the degree of impairment; AUC0-inf was 1.5, 1.7 and 2.6 times that of healthy subjects in moderate, severe and end-stage disease.1 Marier and colleagues (Pharsight Corporation, Montreal, and co-authors), in the Journal of Clinical Pharmacology in 2008, gave daily subcutaneous teduglutide for 8 days to 64 healthy subjects in a double-blind, randomised, placebo-controlled ascending-dose study.3 The doses were 10, 15, 20, 25, 30, 50 and 80 mg of a 50-mg/mL formulation and 20 mg of a 20-mg/mL formulation, so they ran well above the label's per-kilogram dose.3 Exposures on days 1 and 8 were "very similar", and apparent clearance with the 50-mg/mL formulation was constant over the dose range (0.155 L/h/kg in men, 0.159 L/h/kg in women); peak concentration and total exposure with the 20-mg/mL formulation (1.0 mL) were approximately 15% and 78% higher than with the 50-mg/mL formulation (0.4 mL).3 The authors wrote that injection site pain "increased as a function of dose and injected volume", and that all but 1 adverse event was assessed as mild or moderate in severity.3 The PubMed record for this study carries no funding statement and no stated limitations.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Jeppesen and colleagues, STEPS, Gastroenterology 20124 | Randomised, placebo-controlled, 24-week study; sponsor Shire (registry)4,9 | 86 adults with short bowel syndrome and intestinal failure, dependent on parenteral support4,9 | Teduglutide 0.05 mg/kg once daily subcutaneously (n = 43) or placebo (n = 43); 24 weeks4 | Responders (more than 20% reduction in parenteral support at weeks 20 and 24): 27/43 (63%) against 13/43 (30%), P = .002; 1-day or more reduction in weekly support 21/39 (54%) against 9/39 (23%), P = .005; study discontinuation for adverse events 2 against 34 |
| Jeppesen and colleagues, dose-ranging phase 3 study, Gut 20115 | Randomised, double-blind, placebo-controlled, three-arm, 24-week study; authors consultants to NPS Pharmaceuticals and Nycomed; sponsor Shire (registry)5,10 | 83 patients with SBS and intestinal failure5 | Teduglutide 0.10 mg/kg/day (n = 32), 0.05 mg/kg/day (n = 35) or placebo (n = 16), once daily subcutaneously; 24 weeks5 | Graded response score (primary): 0.10 mg/kg/day not significant against placebo (p=0.16); 0.05 mg/kg/day p=0.007 in an ad hoc analysis; responder rate (20% or greater reduction at weeks 20 and 24): 25% (8/32) on 0.10 mg/kg/day, 46% (16/35) on 0.05 mg/kg/day and 6% (1/16) on placebo (p=0.17 and p=0.005); three teduglutide-treated patients weaned off parenteral support; serious adverse events in 31%, 34% and 37% (placebo, 0.10, 0.05); discontinuation for an adverse event in 6%, 6% and 17%5 |
| Iyer and colleagues, pooled post hoc analysis, JPEN 20176 | Post hoc, descriptive analysis pooled from 5 trials; funded by NPS Pharmaceuticals (a Shire subsidiary)6 | 134 adults who received teduglutide 0.05 mg/kg/d6 | Teduglutide 0.05 mg/kg/d for up to 42 months across the pooled studies6 | 16 of 134 gained oral or enteral autonomy after a median of 5 years of parenteral support dependence and 89 weeks of treatment; no between-group comparisons were performed6 |
| Chiba and colleagues, infants and children, Journal of Pediatric Gastroenterology and Nutrition 20237 | Two open-label phase 3 core studies and one extension; supported by Takeda7 | 12 infants and 8 children in the core studies, 2 infants and 7 children in the extension study7 | Teduglutide 0.05 mg/kg/day; 24-week core studies, extension to up to 48 weeks in total7 | At 24 weeks, 20% or greater reduction in parenteral support in 4 infants (57.1%) and 4 children (66.7%) on teduglutide and 2 infants (50.0%) on standard of care; 2 children reached enteral autonomy7 |
| Buchman and colleagues, Crohn's disease pilot, Inflammatory Bowel Diseases 20108 | Pilot, randomised, double-blind, placebo-controlled, dose-ranging study8 | 100 subjects with moderate-to-severe Crohn's disease enrolled, 71 completed8 | Teduglutide 0.05, 0.10 or 0.20 mg/kg daily subcutaneously, or placebo; 8 weeks8 | Numerically higher response and remission rates with teduglutide; at 0.2 mg/kg/d, 44% response and 32% remission against 32% and 20% with placebo; adverse events "were not different between placebo and active treatment groups"8 |
The Crohn's disease study is not a label use; the US and European labels list short bowel syndrome.1,2
Deeper analysis: STEPS (Jeppesen, Gastroenterology 2012)
Jeppesen and colleagues, from Rigshospitalet in Copenhagen, reported the 24-week multicenter STEPS trial in Gastroenterology in 2012.4 The registry entry describes a completed randomised, parallel phase 3 trial of 86 participants, masked for participant, care provider, investigator and outcomes assessor.9 The primary endpoint was the number of responders, patients with a reduction of more than 20% from baseline in parenteral support volume at weeks 20 and 24.4 The primary result was 27/43 (63%) responders on teduglutide against 13/43 (30%) on placebo (P = .002).4 Mean weekly parenteral support fell by 4.4 ± 3.8 L at week 24 from a baseline of 12.9 ± 7.8 L on teduglutide, and by 2.3 ± 2.7 L from 13.2 ± 7.4 L on placebo (P < .001).4 The placebo group also lowered its parenteral support, by 2.3 L of weekly volume against 4.4 L on teduglutide.4 Teduglutide "increased plasma concentrations of citrulline, a biomarker of mucosal mass".4 The safety population was 85 participants, 42 on teduglutide and 43 on placebo; serious adverse events were reported by 15 of the 42 on teduglutide and 12 of the 43 on placebo.9 The lead sponsor named in the registry is Shire, with Nycomed as collaborator, and the PubMed record for the paper holds no funding statement, disclosure statement or limitations text; its full text was not in PubMed Central.9,4 A related paper from the same group states that the authors have served as consultants for NPS Pharmaceuticals and Nycomed GmbH, and a later pooled analysis states that its last author (PBJ) received research support and was a consultant, advisory board member and study investigator for NPS Pharmaceuticals.5,6 The US label reports the same trial as Study 1 (NCT00798967) with a mean patient age of 50 years and a stoma in 45% (38/85).1
Deeper analysis: the dose-ranging study (Jeppesen, Gut 2011)
Jeppesen and colleagues reported a 24-week, double-blind, placebo-controlled phase 3 study in Gut in 2011, run at 32 centres in several countries, with 83 patients randomised to teduglutide 0.10 mg/kg/day (n = 32), 0.05 mg/kg/day (n = 35) or placebo (n = 16).5 The primary endpoint was a graded response score; the paper reports that the higher dose "did not have a statistically significant effect compared with placebo (8/32 vs 1/16, p=0.16)", while the 0.05 mg/kg/day dose "had a significant effect (16/35, p = 0.007)".5 In the results section the graded response score comparisons are p=0.16 for 0.10 mg/kg/day and p=0.007 for 0.05 mg/kg/day, and the counts 8/32 vs 1/16 and 16/35 belong to the responder rate, with p=0.17 and p=0.005.5 The authors note that "Contrary to expectation of a dose response, teduglutide at 0.10 mg/kg/day did not meet statistical significance", and describe the 0.05 mg/kg/day result as an ad hoc analysis.5 They also report that "Neither active treatment arms resulted in a significant reduction in the number of days on parenteral support" and that absolute parenteral volume "only tended to decrease compared with placebo (p=0.08)".5 Three quality of life instruments (SF-36, EuroQol EQ-5D and IBDQ) "indicated no major effect on quality of life parameters (data not shown)".5 Secondary results included that villus height, plasma citrulline concentration and lean body mass "were significantly increased with teduglutide compared with placebo", and three teduglutide-treated patients were completely weaned off parenteral support.5 Of the 83 patients, 79 (95%) had at least one adverse event; the table lists study discontinuation for an adverse event in 1 (6%) on placebo, 2 (6%) on 0.10 mg/kg/day and 6 (17%) on 0.05 mg/kg/day.5 The paper reports that "No deaths were reported during the active treatment phase of the study" and that one patient died from a bleeding ulcer during screening.5 The authors name limitations: "endogenous postprandial meal-stimulated GLP-2 production was not measured", the quality of life tools "were not specific for patients with SBS", and the study "was likely to be underpowered to detect clinically meaningful changes".5 The text read has no funding statement; the competing interests line reads "The authors have served as consultants for NPS Pharmaceuticals and Nycomed GmbH", and the contributors note says "The sponsor and the investigators shared the role in the study design".5 The registry entry for NCT00081458 names Shire as lead sponsor and lists an enrolment count of 84.10 The US label describes the same study as Study 3 and says its analysed population contained one less patient in the 0.1 mg/kg/day group, hence n=32 in that group.1
Deeper analysis: independence from parenteral support (Iyer, JPEN 2017)
Iyer and colleagues (Mount Sinai Medical Center and co-authors) pooled five adult teduglutide studies, two 24-week placebo-controlled trials and three extensions, in a post hoc analysis of patients who stopped needing parenteral support while on 0.05 mg/kg/d.6 Of 134 patients, 16 gained oral or enteral autonomy; most had colon-in-continuity (12/16), but the authors report no significant difference in the frequency of independence between those with and without colon-in-continuity.6 All 16 had at least one treatment-emergent adverse event, 19 treatment-emergent serious adverse events occurred in 13 patients, and teduglutide-specific antibodies were detected in 3 of 16 (19%) patients with no neutralizing antibodies.6 The paper notes that "no patient in the placebo groups within the subset of randomized controlled studies was weaned of PS", and that after stopping, 12 of 25 responders "required increases in PS" in a separate post hoc analysis it cites.6 The authors state that "This study was limited by the small patient sample size", that the pooled studies had differing weaning algorithms, and that patients "were managed under strict clinical trial protocols".6 The research was funded by NPS Pharmaceuticals, a wholly owned indirect subsidiary of Shire; two authors (BL and NNY) "were employees of NPS Pharmaceuticals, Inc, at the time the studies were conducted", and the last author (PBJ) "received research support and was a consultant, advisory board member, and study investigator" for the company.6
Deeper analysis: infants and children (Chiba, 2023)
Chiba and colleagues (Showa University, Tokyo, and co-authors) combined two open-label phase 3 core studies and one extension in infants and children with SBS and intestinal failure, 12 infants and 8 children in the core studies.7 In infants, 57.1% on teduglutide and 50.0% on standard of care had a 20% or greater reduction in parenteral support at week 24, so the proportion was similar between arms; the mean parenteral volume reduction was 34.2 ± 18.8% on teduglutide (n = 6) and 16.8 ± 16.4% on standard of care (n = 3).7 No infants reached enteral autonomy, and two children did; the authors say that adverse events were "predominantly mild-to-moderate in severity" and that no deaths were reported.7 The paper states that "Only one serious AE (abdominal pain) was considered related to teduglutide".7 Two infants (one standard of care, one teduglutide) discontinued in the core period by parental withdrawal, and one child discontinued owing to a treatment-emergent adverse event.7 The authors write that "A limitation of these studies was the small sample sizes", and that the open-label design "may have biased the prescription of PS, with patients receiving teduglutide being weaned off more aggressively than those receiving SoC".7 The work "was supported by Takeda Pharmaceuticals, Inc", the funder "participated in the study design, data collection, data analysis, data interpretation", and one author is a Takeda employee and stockholder, with others also employed by Takeda.7 The US label separately describes its pediatric Study 5, a 24-week multicenter study of 59 patients aged 1 year through 17 years in which patients chose teduglutide or standard of care.1
Doses reported in studies and on labels
The app lists a typical range of 1 to 5 mg/day, whereas the labels and trials below express doses per kilogram of body weight; the US label supplies 5 mg of teduglutide per vial.1
| Source | Population | Dose, route and length | Comparator and n |
|---|---|---|---|
| US label (Gattex)1 | Adults and pediatric patients 1 year and older with SBS dependent on parenteral support1 | 0.05 mg/kg once daily, subcutaneous1 | Not applicable (label) |
| US label, renal impairment1 | Adults and pediatric patients with moderate or severe renal impairment or end-stage renal disease (eGFR less than 60 mL/min/1.73 m2)1 | 0.025 mg/kg once daily, subcutaneous1 | Not applicable (label) |
| European product information (Revestive)2 | Adults, and patients from 4 months corrected gestational age with SBS2 | 0.05 mg/kg body weight once daily for adults2 | Not applicable (product information) |
| STEPS, Jeppesen 20124 | Adults with SBS and intestinal failure4 | 0.05 mg/kg/d subcutaneous, once daily, 24 weeks4 | Placebo, n = 43; teduglutide n = 434 |
| Dose-ranging study, Jeppesen 20115 | Adults with SBS and intestinal failure5 | 0.10 mg/kg/day (n = 32) or 0.05 mg/kg/day (n = 35), subcutaneous, once daily, 24 weeks; the US label calls 0.1 mg/kg/day "not a recommended dosage"5,1 | Placebo, n = 165 |
Side effects reported
Sources in this part
The US label lists the most common adverse reactions (10% or more) as abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload and hypersensitivity.1 These rates come from 136 adults with SBS in two randomised, placebo-controlled, 24-week studies (Studies 1 and 3).1 Among 53 patients with a stoma in those studies, gastrointestinal stoma complications occurred in 42% (13/31) on 0.05 mg/kg/day and 14% (3/22) on placebo.1 In those studies there were 2 cases of congestive heart failure (3%) in the teduglutide arm, one serious.1 The label reports intestinal obstruction in 3/77 (4%) on 0.05 mg/kg/day and 3/32 (9%) on 0.1 mg/kg/day, with "No cases of intestinal obstruction" in the placebo group.1 Three patients were diagnosed with cholecystitis, all on 0.05 mg/kg/day and all with a prior history of gallbladder disease, with no cases on placebo.1 In the placebo-controlled studies, intestinal polyps were diagnosed in 1/59 (2%) on placebo and 1/109 (1%) on 0.05 mg/kg/day, and the label lists 12 further polyp cases in the extension studies, including colorectal villous and tubular adenomas.1 Three adults were diagnosed with malignancy in the adult studies, all male and all on 0.05 mg/kg/day in Study 2.1 The label states that, "Based on the pharmacologic activity and tumor findings in the rat and mouse carcinogenicity studies", teduglutide has the potential to cause hyperplastic changes including neoplasia; this is an animal finding plus a pharmacological inference, not a result in people.1 The label records one adult on prazepam who "experienced a dramatic deterioration in mental status progressing to coma during the first week" of treatment, and lists potential increased absorption of concomitant oral drugs as a warning.1 Anti-teduglutide antibodies were found in 3% (2/60) of adults at Month 3, 17% (13/77) at Month 6, 24% (16/67) at Month 12, 33% (11/33) at Month 24 and 48% (14/29) at Month 30; the label states that antibody formation has not been associated with clinically relevant safety findings, reduced efficacy or changed pharmacokinetics.1
Bloodwork and markers
Sources in this part
The app lists no health markers to monitor for teduglutide. The US label lists bilirubin, alkaline phosphatase, lipase and amylase as baseline laboratory assessments for adults and pediatric patients.1 It also states that these are obtained within 6 months before starting and "at least every 6 months" afterward, or more often if needed.1 For adults, the label calls for a colonoscopy and upper GI endoscopy with removal of polyps within 6 months before starting, a follow-up at the end of 1 year, and subsequent examinations every 5 years or more often as needed.1 For pediatric patients the label calls for fecal occult blood testing before starting and annually, with colonoscopy or sigmoidoscopy after 1 year.1 Plasma citrulline, described in STEPS as a biomarker of mucosal mass, rose with teduglutide, though the pooled independence analysis states that "The possible role of citrulline as a biomarker remains unclear".4,6
Regulatory and anti-doping status
The US label gives 2012 as the initial approval year and lists short bowel syndrome in adults and in pediatric patients 1 year and older who depend on parenteral support.1 The European product information lists patients from 4 months corrected gestational age with SBS and states a first authorisation date of 30 August 2012.2 The WADA 2026 Prohibited List, class S2 (peptide hormones, growth factors, related substances and mimetics), is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" and covers "other substances with similar chemical structure or similar biological effect(s)".11 The text of the 2026 list cited here does not name teduglutide or any other GLP-2 analog in S2.1 to S2.3.11 Whether the list's general wording reaches teduglutide is a question about how the list is applied, which these sources do not answer.
Storage and handling
Sources in this part
The US label states that, prior to dispensing, the 5 mg one-vial kits are stored refrigerated at 2°C to 8°C and not frozen, and that after dispensing by the pharmacist they are stored at room temperature up to 25°C, also not frozen, with a 90-day "use by" dating.1 The European product information for Revestive says to store in a refrigerator and not to freeze.2
What is not known
Sources in this part
On 16 November 2026, the query "teduglutide Crohn's disease randomized" in PubMed returned 4 records and the query "teduglutide Crohn's disease" returned 3 entries; one randomised Crohn's disease trial is cited here, and no search was run for other gut-healing uses, so whether controlled trials exist for them is not established here. The one Crohn's disease trial cited here was a pilot dose-ranging study whose authors concluded that "Further clinical investigation of this growth factor is warranted".8 The app's notes say the community explores teduglutide for gut healing and describe that use as unstudied; among the sources cited here, the only trial outside short bowel syndrome is the Crohn's disease pilot, whose authors concluded that teduglutide is potentially effective for inducing remission and mucosal healing in active moderate-to-severe Crohn's disease and that further clinical investigation is warranted.8 The long-term cancer question is open in the European product information, which says the clinical studies "could neither exclude nor confirm such an increased risk".2 The STEPS paper's full text and limitations section were not available among the sources read, so its authors' own stated limitations are not reported here.
Frequently asked questions
What is the half-life of teduglutide?
Is teduglutide a GLP-1 drug?
The Gattex label describes teduglutide as a glucagon-like peptide-2 (GLP-2) analog that binds glucagon-like peptide-2 receptors.1
What is the bioavailability of subcutaneous teduglutide?
The US label gives an absolute bioavailability of 88% in healthy subjects, which matches the app's 88%.1
How long does teduglutide take to reach its peak level?
What is teduglutide approved for?
Is teduglutide banned by WADA?
The 2026 WADA Prohibited List text cited here does not name teduglutide, and its S2 class covers "other substances with similar chemical structure or similar biological effect(s)".11
What did the main trial of teduglutide show?
In STEPS, 27/43 (63%) of adults on teduglutide 0.05 mg/kg/d and 13/43 (30%) on placebo were responders, defined as more than 20% reduction in parenteral support volume at weeks 20 and 24 (P = .002); at week 24 the mean weekly reduction was 4.4 L on teduglutide and 2.3 L on placebo.4
What are the most common side effects of teduglutide?
The US label lists abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload and hypersensitivity as adverse reactions in 10% or more of patients.1
Does teduglutide carry a polyp or cancer warning?
The US label has a warning on acceleration of neoplastic growth and lists intestinal polyps among the adverse reactions of special interest.1
Guides, tools and comparisons
References
- Takeda Pharmaceuticals America. Gattex (teduglutide) for injection, for subcutaneous use. US prescribing information, DailyMed version 20, 18 September 2025. DailyMed label
- European Medicines Agency. Revestive: summary of product characteristics (EPAR product information). EMA product information
- Marier JF, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 2008. PMID 18974283
- Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology 2012. PMID 22982184
- Jeppesen PB, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011. PMC3112364
- Iyer KR, et al. Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome. JPEN J Parenter Enteral Nutr 2017. PMC5639959
- Chiba M, et al. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support. J Pediatr Gastroenterol Nutr 2023. PMC10412081
- Buchman AL, et al. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010. PMID 19821509
- ClinicalTrials.gov. NCT00798967: Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects (STEPS). Registry entry. NCT00798967
- ClinicalTrials.gov. NCT00081458: Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome. Registry entry. NCT00081458
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list